10-K: Enanta Pharmaceuticals Reports FY25 Results, Advances Pipeline

Enanta Pharmaceuticals, Inc. reported its fiscal year 2025 results, highlighting progress in its RSV and immunology pipelines, alongside a decrease in HCV royalty revenue and continued operating losses.

Summary

• Net loss for fiscal year 2025 was $81.9 million, an improvement from $116.0 million in fiscal year 2024.
• Total revenue decreased to $65.3 million in fiscal year 2025 from $67.6 million in fiscal year 2024, primarily due to lower AbbVie HCV sales.
• Research and development expenses decreased by $24.7 million to $106.7 million in fiscal year 2025, mainly due to the timing of RSV clinical trials.
• Immunology program costs increased by $10.2 million as the company advances this new therapeutic area of focus.
• Cash, cash equivalents, and short-term marketable securities totaled $188.9 million as of September 30, 2025.
• The company believes existing capital, retained HCV royalties, and proceeds from its October 2025 public offering will fund operating expenses and capital expenditure requirements into fiscal 2029.
• Positive topline results were announced for a Phase 2b zelicapavir study in high-risk adults for RSV (September 2025) and a Phase 2 pediatric study (December 2024).
• Positive topline results for EDP-323 in a Phase 2a challenge study of healthy adults infected with RSV were announced in September 2024.
• The FDA approved MAVYRET as the first and only treatment for acute HCV infection in June 2025.
• An Investigational New Drug (IND) application for the KIT inhibitor EDP-978 is expected to be filed in Q1 2026.
• IND-enabling activities have been initiated for the STAT6 inhibitor EPS-3903, with an IND filing goal in H2 2026.
• The company is appealing a U.S. District Court's December 2024 summary judgment ruling that its 953 Patent (related to Paxlovid litigation) was invalid, with an appeal filed in February 2025.
• A patent infringement action was filed in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain subsidiaries on August 20, 2025.

Sentiment

Score: 7

Explanation: While revenue declined and operating losses continue, the significant progress in multiple clinical programs, particularly the positive RSV trial results, and the extended cash runway from the recent capital raise, indicate strong operational execution and future potential in key therapeutic areas, despite the patent litigation setback.

Positives

• Net loss improved to $(81.9) million in FY2025 from $(116.0) million in FY2024, indicating a reduction in losses.
• Positive topline results from the Phase 2b zelicapavir study in high-risk adults for RSV demonstrated a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms (2.2 days faster for overall efficacy population, 6.7 days faster for HR3 population).
• The zelicapavir high-risk adults study also showed a lower hospitalization rate for treated patients (1.7%) compared to placebo (5.0%), with no RSV-related hospitalizations attributed to zelicapavir by investigators.
• Positive topline results from the first-in-pediatrics Phase 2 study of zelicapavir for RSV showed a favorable safety profile and an antiviral effect, with viral load decline peaking at 0.7 log on Day 9 compared to placebo.
• The Phase 2a human challenge study of EDP-323 for RSV demonstrated highly statistically significant reductions in viral load AUC (85-87%) and total symptom score AUC (66-78%) compared to placebo.
• The FDA approved MAVYRET as the first and only treatment for acute HCV infection in June 2025, expanding its market indication.
• The company's cash, cash equivalents, and short-term marketable securities of $188.9 million as of September 30, 2025, combined with proceeds from an October 2025 public offering, are projected to fund operations into fiscal 2029.
• Advancement of the immunology pipeline with the selection of EDP-978 as a clinical candidate for KIT inhibitors (IND expected Q1 2026) and EPS-3903 as a lead development candidate for STAT6 inhibitors (IND goal H2 2026).

Negatives

• Total revenue decreased to $65.3 million in FY2025 from $67.6 million in FY2024, primarily due to lower reported HCV sales by AbbVie.
• The company expects to have continuing operating losses for the foreseeable future.
• 54.5% of future MAVYRET/MAVIRET royalties are paid to OMERS through June 30, 2032, limiting the company's retained cash flow from HCV sales.
• Worldwide sales of leading HCV therapies have declined significantly from $23 billion in 2015 to $2.9 billion in 2024, and $2.0 billion through the first nine months of calendar 2025.
• No effect was observed on the primary endpoint of time to partial resolution of symptoms in the Phase 2b zelicapavir high-risk adults study.
• A U.S. District Court issued a summary judgment ruling in December 2024 that the asserted claims of the company's 953 Patent, central to its patent infringement suit against Pfizer regarding Paxlovid, were invalid.

Risks

• The company will require substantial additional funding to achieve its goals, and a failure to obtain this funding could force delays, limits, reductions, or termination of product development efforts.
• Revenues are substantially dependent on AbbVie's success selling MAVYRET/MAVIRET, which may experience lower sales volume due to reduced diagnoses and treatment rates of HCV.
• AbbVie's MAVYRET/MAVIRET faces intense competition from other HCV products and therapies, including competition for exclusive arrangements with third-party payors and governmental entities, as well as price competition.
• 54.5% of reported revenues after June 30, 2023, represent payments that go directly to OMERS, subject to a cap on aggregate payments.
• The company expects to have continuing operating losses for the foreseeable future, especially with increasing research and development expenses for advancing programs.
• Many preclinical and clinical development activities must be contracted out to contract research organizations (CROs) at significant expense, which are expected to increase substantially for registrational clinical studies.
• Numerous companies are developing potential therapies for RSV, type 2 immune, and mast-cell-driven diseases, which may result in others discovering, developing, or commercializing products before or more successfully than the company.
• In most disease areas of current R&D efforts, other companies have product candidates that are more advanced.
• If the company is not first to market or sufficiently differentiated with one of its product candidates, its competitive position could be compromised.
• Clinical drug development involves a lengthy and expensive process with uncertain timelines, uncertain outcomes, and evolving clinical endpoints for regulatory approvals.
• Changes in regulatory requirements, policies, and guidelines could delay the time required to reach regulatory approval.
• The results of preclinical studies and early clinical trials may not be predictive of later-stage clinical trials, and several companies have suffered setbacks in advanced trials despite promising early results.
• Clinical trials may be suspended or terminated at any time for safety-related reasons, such as undesirable side effects.
• Testing clinical candidates in combination with other compounds may have adverse consequences for the combination and the monotherapy.
• The company may delay or terminate the development of a product candidate at any time if the perceived market or commercial opportunity does not justify further investment.
• The company could be unsuccessful in obtaining or maintaining adequate patent protection for its product candidates, or issued patents may be found invalid or unenforceable.
• There is a risk that product candidates may infringe patents that are currently issued or that are issued in the future.
• Reliance on third parties to manufacture clinical drug supplies and conduct clinical trials introduces risks related to performance, regulatory compliance, and supply chain disruptions.
• Unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives (e.g., Inflation Reduction Act, state price controls) could harm the business.
• The regulatory pathway for approval of a therapeutic treatment for COVID-19 is continually evolving and may result in unexpected challenges and longer timelines.
• Failure to comply with ongoing FDA obligations and continued regulatory review in other jurisdictions could result in significant additional expense, labeling restrictions, or market withdrawal.
• The company's reliance on third-party manufacturers, including those in China, exposes it to risks of product supply disruption, increased costs, and geopolitical unrest (e.g., proposed BIOSECURE Act).
• Internal computer systems, or those of collaborators, CROs, or other contractors, may fail or suffer security breaches, leading to disruptions, data loss, or liability.
• Relationships with customers and third-party payors are subject to anti-kickback, fraud, and abuse laws, which could expose the company to criminal sanctions, civil penalties, and reputational harm.
• The company's stock price has been, and is likely to continue to be, volatile.
• The ability to use future net operating loss carryforwards and research and development tax credit carryforwards may be limited under Section 382 of the Internal Revenue Code.

Future Outlook

The company expects to have continuing operating losses for the foreseeable future. It believes its existing cash, retained HCV royalties, and proceeds from the October 2025 public offering will enable it to fund operations into fiscal 2029. The company is evaluating potential partnership opportunities to advance its RSV programs to the next stage of clinical development. It plans to expand its immunology presence with a third program in the fourth quarter of 2025, with IND filings for its KIT inhibitor EDP-978 expected in Q1 2026 and for its STAT6 inhibitor EPS-3903 in H2 2026.

Management Comments

• "We are evaluating potential partnership opportunities to advance our RSV programs to the next stage of clinical development."
• "We plan to expand our presence in immunology with the introduction of a third program in the fourth quarter of 2025."
• "Based on our operating plan, we believe that our existing cash, cash equivalents, and short-term marketable securities as of September 30, 2025, as well as the cash flows from our retained portion of future HCV royalties and the proceeds from our public offering in October 2025, will enable us to fund our operating expenses and capital expenditure requirements into fiscal 2029."

Industry Context

The HCV market has seen a significant decline in worldwide sales, from a peak of $23 billion in 2015 to $2.9 billion in 2024, primarily due to increased competition, payer discounts, and a reduction in the initial wave of diagnosed chronic HCV patients. In the RSV market, while new prophylaxis options (monoclonal antibodies and vaccines) have emerged, a substantial unmet need for safe and effective antiviral treatments for established infections persists due to limitations in passive immunity duration, sub-optimal uptake, and breakthrough infections. The immunology markets for conditions like urticaria and atopic dermatitis are projected to be multi-billion dollar opportunities by 2030/2032, indicating significant unmet needs despite existing therapies. The pharmaceutical and biotechnology industries are intensely competitive, with many larger companies possessing greater resources and more advanced drug candidates across all therapeutic areas the company targets.

Comparison to Industry Standards

• MAVYRET/MAVIRET remains the only 8-week pan-genotypic HCV treatment in over 50 countries, offering a shorter treatment duration compared to 12 weeks for competitors like Gilead's EPCLUSA and HARVONI.
• EPS-3903 (STAT6 inhibitor) demonstrates in vivo efficacy comparable to dupilumab (an anti-mouse IL-4/IL-13 antibody) in multiple disease models of asthma and AD, positioning it as a potential oral alternative to a leading biologic.
• For Chronic Spontaneous Urticaria (CSU), clinical proof of concept for KIT inhibition has been established with positive Phase 2 data for anti-KIT monoclonal antibodies (e.g., Celldex's barzolvolimab in Phase 3), suggesting best-in-disease efficacy, which Enanta's preclinical oral KIT inhibitor EDP-978 aims to replicate.
• In Atopic Dermatitis (AD), the treatment landscape is dominated by biologics (DUPIXENT, ADBRY, EBGLYSS) and JAK inhibitors (RINVOQ, CIBINQO) with known safety concerns; Enanta's STAT6 inhibitor aims to offer a selective oral option without these safety profiles.
• Enanta's RSV N-protein (zelicapavir) and L-protein (EDP-323) inhibitors target viral replication, a mechanism that may offer advantages over fusion inhibitors by blocking new virion production and demonstrating a higher barrier to resistance.

Corporate Governance

Legal Proceedings

• Filed a patent infringement suit in the United States District Court for the District of Massachusetts on June 21, 2022, against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the '953 Patent) in the manufacture, use, and sale of Pfizer's COVID-19 antiviral, Paxlovid.
• On December 23, 2024, the U.S. District Court issued a summary judgment decision ruling that the asserted claims of the '953 Patent were invalid.
• On February 3, 2025, the company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit regarding the '953 Patent litigation.
• On August 20, 2025, the company filed a patent infringement action in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the '265 Patent) in connection with Paxlovid sales in 18 EU member states.

Stakeholder Impact

• Shareholders: Potential for increased value from pipeline advancements in RSV and immunology, but also risks from declining HCV royalties, ongoing operating losses, and the unfavorable initial ruling in the Pfizer patent litigation. The recent public offering diluted existing shares but extended the cash runway.
• Employees: Continued investment in R&D and expansion of immunology programs suggest stable to growing opportunities. The company provides competitive compensation and benefits.
• Customers/Patients: New FDA approval for MAVYRET in acute HCV, and promising clinical data for RSV and immunology candidates, indicate potential for new and improved treatments for significant unmet medical needs.
• Creditors: The royalty sale agreement with OMERS creates a liability, but the company's strong cash position and extended funding runway mitigate immediate concerns.
• Suppliers/CROs: Continued reliance on third-party manufacturers and CROs for R&D activities, indicating ongoing business for these partners.

Next Steps

• Evaluate potential partnership opportunities to advance RSV programs to the next stage of clinical development.
• File an Investigational New Drug (IND) application for KIT inhibitor EDP-978 in Q1 2026.
• Initiate IND-enabling activities for STAT6 inhibitor EPS-3903 with a goal of filing an IND in H2 2026.
• Expand presence in immunology with the introduction of a third program in Q4 2025.
• Continue to prosecute patent infringement litigation against Pfizer in the United States Court of Appeals for the Federal Circuit.
• Continue patent infringement action in the Unified Patent Court (UPC) of the European Union against Pfizer Inc.

Key Dates

Recommendation

While the company faces challenges with declining HCV royalty revenue and an unfavorable initial ruling in the Pfizer patent litigation, the positive clinical trial results for its wholly-owned RSV and immunology programs demonstrate strong internal R&D capabilities and potential for future value creation. The recent capital raise extends the funding runway, providing time for these programs to advance. However, the early stage of the immunology pipeline, the need for partnerships for RSV, and the ongoing legal battle introduce significant uncertainties. A 'Hold' recommendation reflects the balance between the promising pipeline developments and the inherent risks and financial pressures.

Keywords

Biotechnology, Pharmaceuticals, Virology, Immunology, RSV, Hepatitis C, HCV, MAVYRET, MAVIRET, Glecaprevir, KIT inhibitor, STAT6 inhibitor, Chronic Spontaneous Urticaria, CSU, Atopic Dermatitis, AD, Zelicapavir, EDP-323, EDP-978, EPS-3903, Clinical Trials, Drug Development, Patent Litigation, Pfizer, Paxlovid, Capital Raise, SEC Filing, 10-K